VALSARTAN

Among Lotus best selling products, VALSARTAN Capsules are a medicine for primary hypertension or high blood pressure. Valsartan first came to market in America in 1996, known as Diovan. The Novartis AG version of the Diovan product generated almost 21 percent of that company's 2005 revenues from branded pharmaceuticals. Novartis predicts the drug might be its first to generate annual revenues of more than $5 billion.

VALSARTAN can be prescribed in a broader range of heart failure patients and is no longer limited to those intolerant of ACE inhibitors. VALSARTAN will treat high blood pressure, high-risk heart attack survivors and people with heart failure. Every day, more than 3,000 patients suffer a heart attack in the United States. Although there have been significant advances in recent years, death following a heart attack remains unacceptably high.

High blood pressure, a disease which affects one billion people globally JNC-VII (2), greatly increases the risk of suffering a heart attack or developing heart failure. People who have suffered a heart attack are at greater risk of repeat attacks or death and may also progress to heart failure. In fact, within six years, nearly one-third of all heart attack survivors will be disabled with heart failure, a progressive condition in which the heart's muscle weakens after injury from other cardiovascular conditions, such as a heart attack or high blood pressure.

Millions of patients will rely on VALSARTAN to help them improve their health and maintain healthier blood pressure goals. Now, based on results from one of the largest mega trial programs in the ARB class, VALSRTAN has demonstrated additional benefits that can address the needs of an even broader spectrum of cardiovascular patients, LOTUS is committed to developing the full clinical potential of this agent.

The Company’s goal is make VALSARTAN the number one prescribed brand in its class of high blood pressure medications in China. It is an angiotensin II receptor blocker, also called an ARB.1 Here’s how VASARTAN works to lower blood pressure: Angiotensin II is a chemical in the body that causes blood vessels to narrow.

When you have narrow blood vessels, the heart has to pump harder to get blood through your vessels to your vital organs. This can increase the force of blood against the walls of your blood vessels, as well as your blood vessels' resistance to blood flow. VALSARTAN blocks the effects of angiotensin II that lead to the narrowing of the blood vessels (unhealthy vessel constriction).

VALSARTAN helps your blood vessels relax and widen so your blood can flow more freely, and your heart doesn't have to work as hard to pump blood through your body.

What can Patients can expect from VALSARTAN?

Reduce blood 'stickiness' and improve blood flow through the arteries. Calms and soothes stress and nervous tension. Tones and protects the heart and cardiovascular system. Improves circulation, including chilblains and tingling in the hands and feet. Improves the pumping ability of the heart and reduce irregular heartbeat. Protects against dangerous plaque build up in the coronary arteries and helps to prevent blood clotting, strokes and heart attacks, plus a slight relief of the symptoms of angina.

This website contains forward-looking statements that involve risks and uncertainties, including those relating to the Company's ability to grow its business. Actual results may differ materially from the results predicted and reported results should not be considered as an indication of future performance. The potential risks and uncertainties include, among others, the company's limited operating history, the limited financial resources, domestic or global economic conditions -- especially those relating to China, activities of competitors and the presence of new or additional competition, and changes in Federal or State laws, restrictions and regulations on doing business in a foreign country, in particular China, and conditions of equity markets. More information about the potential factors that could affect the company's business and financial results is included in the Company's filings, available via the United States Securities & Exchange Commission. Occasionally, the Company may select and post articles or opinions of third parties, with no known connection with the Company. These are considered expert or qualified writers about the Chinese economy and its various opportunities and pitfalls. The Company neither endorses nor rejects these views or content, and the articles are offered only for the readers' edification and personal analyses.